On Friday, 17th April 2026, the MU-JHU Care Ltd REVIVE Study team gathered both in person and virtually, for a full-day refresher training and AMR sub-study overview. The program began with registration, introductions, and a knowledge check led by Community Educator Hassan Ssemere, setting up an interactive tone for the day. Brenda Kakayi, our REVIVE Study Investigator, then guided staff members through a detailed protocol refresher while also leading a verbal autopsy refresher session to reinforce data quality and consistency. The agenda included energizing team-building activities and a shared lunch, creating space for connection and reflection. The day concluded with closing remarks and a cake-cutting ceremony, as the team celebrated milestones achieved and reaffirmed their commitment to high-quality research.

About the REVIVE Study

The REVIVE Study is a multi-country clinical trial focused on reducing mortality among people living with Advanced HIV Disease (AHD), particularly in sub-Saharan Africa where the burden remains high. The study investigates whether adding azithromycin prophylaxis to standard HIV care can prevent severe bacterial infections, one of the leading causes of early death in this population. Through rigorous research, REVIVE aims to generate evidence that can improve treatment strategies, strengthen health systems, and ultimately save lives.